MedGenome News Room

MedGenome, Inc has been selected for the 2022 Best of Foster City Award in the Corporate Headquarters category by the Foster City Award Program.

Each year, the Foster City Award Program identifies companies that we believe have achieved exceptional marketing success in their local community and business category. These are local companies that enhance the positive image of small business through service to their customers and our community. These exceptional companies help make the Foster City area a great place to live, work and play.

MedGenome and Emmes are proud to launch a strategic partnership to focus on advancing Rare Disease research.

Patients and families with rare diseases are one of the most underserved communities in medicine today. India and South Asia have the world’s largest population of people affected by rare and inherited disease.

The MedGenome – Emmes partnership will combine patients’ genomic, phenotypic and epidemiological data into custom rare disease registries.

This help bring faster and more innovative treatments to patients around the world who are suffering from rare diseases.

International Finance Corporation, member of the World Bank Group, is investing USD 16.5 million (around Rs 123 crore) in genetic diagnostics and research company MedGenome to increase access to COVID-19 testing in India.

In a paper published in Nature Communications, scientists from MedGenome India/USA, along with an international team of scientists from institutions in India, USA, South Korea, Chile and Australia reported sequencing and analysis of over 150 gallbladder cancer (GBC) samples.

MedGenome, the leading genetic diagnostics, research and data company focused on expanding access for populations in South Asia and other emerging markets today announced an investment of USD 55m led by LeapFrog Investments, a leading specialist investor in emerging markets. Existing investors Sofina and Sequoia also participated in the round.

MedGenome has partnered with Thermo Fisher Scientific to genotype hundreds of thousands of South Asian cohorts using a custom genotyping array. The personalized medicine company hopes to use the new array to inform new consumer and clinical tests, while also making it available to others for research.

Researchers from the GenomeAsia 100K Project have begun to develop a reference dataset of genomes from individuals living in Asia, with the goal of boosting the representation of Asians in genomic research.

MedGenome has introduced the South Asian Research Genotyping Array, which leverages MedGenome’s proprietary database of 2.5 million variants unique to the South Asian population and not available in any publicly available genetic database.

MedGenome, a global leader in personalized medicine, announced the development of a proprietary genotyping array to efficiently enable large-scale genetic studies focused on South Asian populations. The South Asian Research Genotyping Array by MedGenome (“SARGAM”) will be optimized for capturing the unique variants found in South Asian genomes, leveraging MedGenome’s proprietary database of 2.5 million variants that are unique to the South Asian population, and not available in any publicly available genetic database.